An investigational triple-hormone receptor agonist studied for obesity. It is not approved anywhere.
Key takeaway
Retatrutide is designed to act on three receptors at once: GIP, GLP-1, and glucagon. It is in late-stage clinical trials for obesity and related conditions.
At a glance
| FDA status | Not FDA-approved |
|---|---|
| 503A compounding | No 503A pathway: not approved and not on FDA’s bulks lists |
| Body areas | Metabolism & weight |
| Through ScriptMates | Information only |
| Open questions | 1 noted below |
What is retatrutide?
Retatrutide is designed to act on three receptors at once: GIP, GLP-1, and glucagon. It is in late-stage clinical trials for obesity and related conditions.
It is not an approved drug and has no 503A compounding pathway. FDA has warned about unapproved GLP-1-type products sold online.
Dosage forms
No FDA-approved dosage form. A standardized dosage form for human use was not confirmed from the sources below.
Is retatrutide FDA-approved?
Investigational; not approved by FDA. It is not on FDA’s 503A bulks list or in any 503A category.
Can it be prescribed through ScriptMates?
No 503A pathway: not approved and not on FDA’s bulks lists. A partner pharmacy lists it, but it has no lawful 503A pathway today (not approved and not on FDA’s bulks lists).
What we could not confirm
- Catalog items labeled “GLP-3” or “GLP-3R” are assumed to be retatrutide; the catalogs do not name the ingredient.
Sources
- FDA: Bulk drug substances nominated under 503A, Categories 1–3 (May 14, 2026)
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss
Checked October 27, 2026. FDA updates these pages, so confirm before relying on them.